Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. - Wikidata - awgldk - TriplyDB

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

http://www.wikidata.org/entity/Q40370520

about

The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Treating refractory leukemias in childhood, role of clofarabine Myeloid leukemia in Down syndrome Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study.The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant Global characteristics of childhood acute promyelocytic leukemia.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.Combating blood stream infections during induction chemotherapy in children with acute myeloid leukemia: Single center results in India.Diagnostic & prognostic role of microRNAs in paediatric acute myeloid leukaemia.Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India.

P2860

Q24187297-54DEA520-3D78-40C3-AAA7-F5990804D09E Q24193790-F8A8A940-7A23-4805-BC35-85E761A7BA9A Q24234833-761E4DA4-6D99-4EA7-AE07-97D07A8FF712 Q24241602-55DC64EE-6767-4733-B285-D7F2026C48A6 Q24647279-68640F41-C949-43FE-A907-7F57937D3E93 Q27027258-8A04F731-7FAA-4638-BE1D-7E3214DE740F Q28079980-BB00B4DB-5A0D-4053-B787-093B58C97553 Q28486136-E1D50F0E-2B70-416C-B8BC-0331D6B16921 Q33565514-6234F17D-504C-434A-8C4B-77B45DC12D04 Q33779361-2F4EC17C-407E-4D83-A5C3-FFB4384AE4B1 Q34080807-494DCC3C-1EB0-48EC-85D3-72A38DF40A1C Q34325487-03EC03C4-69D3-4ADC-B244-141CD22D1C13 Q34344493-E29A52F3-90B1-4C16-BEE7-A18DE59965E8 Q34764504-BF4E9BBF-073A-4E91-AFF9-0F009F639F47 Q35040531-22EDA926-E024-4FD7-A512-5E2ED2C44CB7 Q35127974-77E0A7F3-09A7-4BB6-928D-DDF3D1ADC365 Q35189037-CC5F6C09-DB5F-4D66-8D43-B8D2346E8882 Q35231673-A899EE6E-C3F6-4B1B-9961-94A8EE52D05C Q35265916-FF68DC90-9182-4B3D-8818-64A51A98293C Q35563658-BC841F74-E5B6-4F5F-920F-4F6C65E33A4E Q35568696-F0BF2A0C-49A7-4876-AB6B-C99E70632442 Q36053792-F1CBCB33-7C7A-40AC-A6CD-770898F6E47B Q36366665-C32A0AF5-4921-4D6E-AE38-C828F040919A Q36407162-6DDBB569-4EAE-48FD-9A12-1028BDE2CF29 Q36661874-F8ECDB9D-031B-4117-8E59-33D42FBFE629 Q37017217-494241BD-6417-4DA0-AF60-3B8D41601D43 Q37121665-3D56C80D-D05C-4236-9885-02B5E396E16A Q37323006-4E73F276-F05A-4449-B10C-BFF14EC306FC Q37364550-DC9A1372-3D3D-4951-BB22-6B8B0462142B Q37874929-B2B2A438-FCF2-45D0-BAE1-12628C2C6536 Q38097334-7FD4EA97-C7DD-4D4E-A48F-40B069676913 Q38112088-698FB215-9BF0-4178-B544-ACA19A9805FC Q38155455-106EB6AC-EB16-40DE-BDE7-276C12D202C5 Q38196743-0C9B66AD-BF1C-48C8-A87E-29C1D15332E0 Q38205864-42B9ED69-536A-4C14-8A33-F968E3B21BE4 Q38345216-53B2AFCC-4A96-4F0C-BB09-3634647C3B88 Q38884168-B7E844C6-CB33-43F9-9DEB-2ECAE0138983 Q39285462-A6EFC90F-5D71-448B-B609-46BF853FF016 Q39477447-0F8CC090-7977-4E2E-9E59-60FD72459093 Q39589791-DDEF4904-5988-40EB-A400-8BC8F6A246DA

P2860

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

http://www.wikidata.org/entity/Q40370520

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Treatment strategies and long- ...... ur consecutive AML-BFM trials.

@en

type

label

Treatment strategies and long- ...... ur consecutive AML-BFM trials.

@en

prefLabel

Treatment strategies and long- ...... ur consecutive AML-BFM trials.

@en

P1433

Q40370520-C40B0913-B1AF-49AF-89CA-A4B37E1BF8CB

P1476

Q40370520-8583334B-60D2-492F-8FC0-F091C253B057

P2093

Q40370520-083D8BD2-9588-4784-8488-4835ED098479

Q40370520-170B8769-5E83-4825-91A0-2FC76595ADFC

Q40370520-182C7AC5-9955-403B-9049-3A18B76E4AB5

Q40370520-314F8604-8069-4607-8CDF-C9937492028F

Q40370520-34261FCA-F76C-43BC-A3F7-283E5BDBA73A

Q40370520-42E837A0-FB79-4387-ACCA-34965885C5DD

Q40370520-502ED1F0-DE94-490D-AE80-F1E4506EEE95

Q40370520-53FD86FC-FF26-479C-9C7E-76ED0971CB74

Q40370520-72C9ACA8-9A69-4EE4-9122-B68B7ACD6E47

Q40370520-C6D6A7D0-4D77-49DC-B758-140198F2F2E7

P2860

Q40370520-09AFB43B-4382-4EA1-AD7D-1D607E84B748

Q40370520-0E329602-970E-42A2-B184-6E7A2F92A477

Q40370520-1648800B-3253-42CD-841B-0C09A1C1444D

Q40370520-1CF46139-49AF-4CB4-A476-904FBE002541

Q40370520-1F91701E-E6D5-4DA2-A299-FFAA17213594

Q40370520-568FAAAB-F0C8-4A5B-B43D-58D757B1FF6D

Q40370520-607AA6A1-503D-4315-8C1C-257B4CD74D41

Q40370520-6486F18F-E400-4F28-82EB-E6508D477FB2

Q40370520-6862984C-BD12-411F-BDA9-4CD0AC3DCA0B

Q40370520-74FB803D-D39D-4637-A461-9E3AA1A3CCDA

P2888

Q40370520-9E7A9FC9-AB3F-4A92-8077-0C9E98F2A279

P304

Q40370520-D94E3D69-4BD9-4B4E-BC4F-1ACC7393D9F1

P31

Q40370520-08529700-4297-46A7-A516-E98A35C0C5CE

P356

Q40370520-6A2A2A86-9823-48EB-A137-E799C6D5E40B

P433

Q40370520-94B82B21-1088-4F05-A6B2-77D4E47DD7D2

P478

Q40370520-42A9515A-3E62-4C54-93D4-535A1A27C32D

P577

Q40370520-B3630CCC-AE4E-406D-BB7C-7DC130EF0D66

P5875

Q40370520-C983677D-7F1A-454E-A7C6-502A6A8F06AA

P6179

Q40370520-876C668B-55EF-4BEE-AAFC-9C3820CC9BC3

P698

Q40370520-6A0D78B9-F6A7-46F3-A219-5970C7112845

P356

P1433

P1476

Treatment strategies and long- ...... ur consecutive AML-BFM trials.

@en

P2093

Creutzig U

http://www.w3.org/2001/XMLSchema#string

Gadner H

http://www.w3.org/2001/XMLSchema#string

Henze G

http://www.w3.org/2001/XMLSchema#string

Hermann J

http://www.w3.org/2001/XMLSchema#string

Jürgens H

http://www.w3.org/2001/XMLSchema#string

Kabisch H

http://www.w3.org/2001/XMLSchema#string

Reinhardt D

http://www.w3.org/2001/XMLSchema#string

Reiter A

http://www.w3.org/2001/XMLSchema#string

Riehm H

http://www.w3.org/2001/XMLSchema#string

Ritter J

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a European view.

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

FLT3-TKD mutation in childhood acute myeloid leukemia.

Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.

Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children.

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.

P2888

P304

2030-2042

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2403920

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7463377

http://www.w3.org/2001/XMLSchema#string

P6179

1038093844

http://www.w3.org/2001/XMLSchema#string

P698

16304570

http://www.w3.org/2001/XMLSchema#string